Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting

Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis Real-World and Clinical Data Focus on Long-Term Efficacy and Safety of Prolia® (Denosumab), Provide Insights on Therapy Compliance in Patients With Postmenopausal Osteoporosis THOUSAND OAKS, Calif., Sept. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Atlanta on Sept. 16-19, 2016. At the congress, Amgen will highlight a diverse set of data acros...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news